Author Contributions
X.L. (Xuelun Luo): Conceptualization, Investigation, Methodology, Data curation, Writing—original draft, Writing—review and editing, Software, Validation, Formal analysis, Visualization. W.Z.: Validation, Data curation, Writing—review and editing. Z.H.: Validation, Data curation, Writing—review and editing. Y.H.: Conceptualization, Validation, Writing—review and editing. J.Z.: Conceptualization, Data curation, Supervision, Formal analysis, Validation, Writing—review and editing. X.L. (Xiaoli Li): Conceptualization, Supervision, Formal analysis, Validation, Writing—review and editing. All authors have read and agreed to the published version of the manuscript.
Figure 1.
Barbed wire frames correspond to the processing type.
Figure 1.
Barbed wire frames correspond to the processing type.
Figure 2.
Primary classification of metabolites detected by metabolomics.
Figure 2.
Primary classification of metabolites detected by metabolomics.
Figure 3.
The first two principal components of PCA distinguish the CK group, EG_20, EG_40, and EG_80 treatment groups.
Figure 3.
The first two principal components of PCA distinguish the CK group, EG_20, EG_40, and EG_80 treatment groups.
Figure 4.
EG_20, EG_40, EG_80 compared with CK’s VIP value graph of common differential metabolites (20 were randomly selected), where the ordinate represents metabolites and the abscess represents VIP value of difference detection. A metabolite is considered to exhibit a significant change in response to treatment when its VIP score exceeds 1. Red means upregulated, blue means downregulated. The asterisk (*) represents an uncertain isomer of the substance.
Figure 4.
EG_20, EG_40, EG_80 compared with CK’s VIP value graph of common differential metabolites (20 were randomly selected), where the ordinate represents metabolites and the abscess represents VIP value of difference detection. A metabolite is considered to exhibit a significant change in response to treatment when its VIP score exceeds 1. Red means upregulated, blue means downregulated. The asterisk (*) represents an uncertain isomer of the substance.
Figure 5.
Upregulated co-differential metabolite enrichment in each pathway.
Figure 5.
Upregulated co-differential metabolite enrichment in each pathway.
Figure 6.
ASD spectra chart. The blue curve represents all the collected spectral data, while the red circles indicate the outlier spectra.
Figure 6.
ASD spectra chart. The blue curve represents all the collected spectral data, while the red circles indicate the outlier spectra.
Figure 7.
ASD spectral classification for different treatments. The length of the error bars represents the standard deviation. *** indicates p < 0.001 based on t-test results.
Figure 7.
ASD spectral classification for different treatments. The length of the error bars represents the standard deviation. *** indicates p < 0.001 based on t-test results.
Figure 8.
The confusion matrix of the optimal model distinguishing CK, EG_20, EG_40, and EG_80 based on ASD spectra. (a) Distinguish by the first day ASD spectrum. (b) Differentiation by next-day ASD spectrum. (c) Distinguish by the third day ASD spectrum. (d) by the fifth day ASD spectrum. (e) Distinguish by the sixth day ASD spectrum.
Figure 8.
The confusion matrix of the optimal model distinguishing CK, EG_20, EG_40, and EG_80 based on ASD spectra. (a) Distinguish by the first day ASD spectrum. (b) Differentiation by next-day ASD spectrum. (c) Distinguish by the third day ASD spectrum. (d) by the fifth day ASD spectrum. (e) Distinguish by the sixth day ASD spectrum.
Figure 9.
ASD spectra distinguish the best model confusion matrix for CK and EG processing. (a) Distinguish by the first day ASD spectrum. (b) Differentiation by next-day ASD spectrum. (c) Distinguish by the third day ASD spectrum. (d) by the fifth day ASD spectrum. (e) Distinguish by the sixth day ASD spectrum.
Figure 9.
ASD spectra distinguish the best model confusion matrix for CK and EG processing. (a) Distinguish by the first day ASD spectrum. (b) Differentiation by next-day ASD spectrum. (c) Distinguish by the third day ASD spectrum. (d) by the fifth day ASD spectrum. (e) Distinguish by the sixth day ASD spectrum.
Figure 10.
ASD spectra combined with spectral preprocessing were used to distinguish the accuracy of CK group and EG group at different times. The length of the error bar indicates the standard deviation. ** indicates p < 0.01, and *** indicates p < 0.001 based on t-test results.
Figure 10.
ASD spectra combined with spectral preprocessing were used to distinguish the accuracy of CK group and EG group at different times. The length of the error bar indicates the standard deviation. ** indicates p < 0.01, and *** indicates p < 0.001 based on t-test results.
Figure 11.
Confusion matrix of the best model for distinguishing time based on ASD spectral data. (a) CK group and (b) EG treatment.
Figure 11.
Confusion matrix of the best model for distinguishing time based on ASD spectral data. (a) CK group and (b) EG treatment.
Figure 12.
Under the selection of feature bands, the average accuracy (bar) and standard deviation (error bar) of the valid set for distinguishing CK and EG at the same time. * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001 based on t-test results.
Figure 12.
Under the selection of feature bands, the average accuracy (bar) and standard deviation (error bar) of the valid set for distinguishing CK and EG at the same time. * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001 based on t-test results.
Table 1.
Daily weather during the experiment.
Table 1.
Daily weather during the experiment.
| 13 September | 14 September | 15 September | 16 September | 17 September | 18 September |
---|
Weather | Cloudy to sunny | Cloudy to overcast | Overcast to moderate rain | Overcast to thunderstorm | Overcast to clear | Cloudy to light rain |
Temperature | 25–36 °C | 25–33 °C | 25–32 °C | 25–28 °C | 25–34 °C | 25–32 °C |
Table 2.
The three groups of EG treatments (EG_20, EG_40, EG_80) had common differential metabolites relative to the CK group. The Type column indicates the direction of metabolite regulation, where “up” represents upregulated metabolites and “down” represents downregulated metabolites.
Table 2.
The three groups of EG treatments (EG_20, EG_40, EG_80) had common differential metabolites relative to the CK group. The Type column indicates the direction of metabolite regulation, where “up” represents upregulated metabolites and “down” represents downregulated metabolites.
Compounds | Class II | Type |
---|
3-Cinnamoyl-5-p-Coumaroylshikimic acid | Phenolic acids | up |
Moroctic Acid methyl ester * | Free fatty acids | up |
Atractyloside B | Sesquiterpenoids | up |
Moroctic Acid * | Free fatty acids | up |
Apigenin 7,4′-diglucoside | Flavones | up |
2-(7-hydroxy-4-methoxy-9,10-dihydrophenanthren-2-yl)-6-(hydroxymethyl)oxane-3,4,5-triol | Others | up |
N-carboxy-N-(2-oxo-2-phenylethyl)-L-alanine | Amino acids and derivatives | up |
2,3-Dihydroxy-12-ursen-28-oic acid * | Triterpene | down |
4-Coumaryl alcohol | Alcohol compounds | up |
Quercetin-3-O-(2″-O-galloyl)Arabinoside | Flavonols | up |
Phenylpyruvate | Phenolic acids | up |
3,3′,5,7-Tetrahydroxy-4′,6-Dimethoxyflavone-7-O-Gentiobioside; (Laciniatin-7-O-Gentiobioside) | Flavonols | up |
Myricetin-3-O-(6″-malony)glucoside * | Flavonols | up |
Luteolin-6-C-arabinoside-7-O-glucoside | Flavones | up |
Camelliagenin A | Triterpene | up |
9-Oxo-10,12-Octadecadienoic Acid | Free fatty acids | up |
Chipericumin B | Others | up |
Phloretate * | Phenolic acids | up |
Maltotriose | Saccharides | down |
Punicic acid | Free fatty acids | up |
3-(Dimethylamino)-2-Phenylacrolein | Alkaloids | up |
13S-Hydroxy-9Z,11E,15Z-octadecatrienoic acid | Free fatty acids | up |
Alangionoside A | Sesquiterpenoids | up |
Methyl 12-phenyldodecanoate * | Free fatty acids | up |
5-(2-Aminopropyl)benzofuran | Alkaloids | up |
16,23:16,30-Diepoxydammar-24-ene-3,20-diol (Jujubogenin) * | Triterpene | down |
22,23-Epoxyiridals | Triterpene | up |
Costunolide Diepoxide | Sesquiterpenoids | up |
5′-Glucosyloxyjasmanic acid * | Organic acids | up |
4-Cinnamoyl-5-p-Coumaroylquinic acid | Phenolic acids | up |
Tuberonic acid glucoside * | Organic acids | up |
4,6-(S)-Hexahydroxydiphenoyl-D-glucose | Tannin | up |
2-Glucosyloxy-4-hydroxybenzeneacetonitrile | Alkaloids | up |
3-Oxolanosta-9(11),24-dien-26-oic acid (Coccinic Acid) | Triterpene | up |
Persicarin (Isohamnetin-3-O-sulfate) | Flavonols | up |
1,3,4,6-Tetra-O-Galloyl-Glucose | Phenolic acids | up |
Coumarin | Coumarins | up |
Roupelliol | Others | up |
Jasmonoyl-L-Isoleucine | Amino acids and derivatives | up |
Pantothenol | Vitamin | down |
14,15-Dehydrocrepenynic acid * | Free fatty acids | up |
2-Oxoadipate | Organic acids | up |
3-Cinnamoyl-5-p-Coumaroylquinic acid | Phenolic acids | up |
Kaempferol | Flavonols | down |
PAz-PC | LPC | up |
Methyl linolenate | Free fatty acids | up |
cis,cis-Muconate | Organic acids | down |
1-O-Feruloyl 2,3-dihydroxypropyl 16-hydroxyhexadecanoate | Free fatty acids | up |
5,6-Dihydroxyindole-5-O-β-glucoside | Plumerane | up |
Table 3.
The mean accuracy (ACTR_Mean) and standard deviation (ACTR_Std) of the training set, as well as the mean accuracy (ACVA_Mean) and standard deviation (ACVA_Std) of the validation set for different models and preprocessing methods (Pre-method). The red font highlights the best preprocessing results of each model. ** indicates a statistically significant difference (p < 0.01, t-test) compared to the best preprocessing method (ACVA_Mean) for each model. *** indicates a highly significant difference (p < 0.001, t-test) relative to the best preprocessing method (ACVA_Mean).
Table 3.
The mean accuracy (ACTR_Mean) and standard deviation (ACTR_Std) of the training set, as well as the mean accuracy (ACVA_Mean) and standard deviation (ACVA_Std) of the validation set for different models and preprocessing methods (Pre-method). The red font highlights the best preprocessing results of each model. ** indicates a statistically significant difference (p < 0.01, t-test) compared to the best preprocessing method (ACVA_Mean) for each model. *** indicates a highly significant difference (p < 0.001, t-test) relative to the best preprocessing method (ACVA_Mean).
Task | Model | Pre-method | ACTR_Mean | ACTR_Std | ACVA_Mean | ACVA_Std |
---|
Treatment | PLSDA | Raw | 1.000 | 0.000 | 0.476 *** | 0.015 |
SG | 1.000 | 0.000 | 0.512 | 0.039 |
MM | 1.000 | 0.000 | 0.528 | 0.025 |
SG + MM | 1.000 | 0.000 | 0.535 | 0.028 |
RF | Raw | 1.000 | 0.000 | 0.421 | 0.046 |
SG | 1.000 | 0.000 | 0.444 | 0.023 |
MM | 1.000 | 0.000 | 0.482 | 0.012 |
SG + MM | 1.000 | 0.000 | 0.455 | 0.042 |
Time | PLSDA | Raw | 1.000 | 0.000 | 0.612 *** | 0.020 |
SG | 1.000 | 0.000 | 0.670 *** | 0.017 |
MM | 1.000 | 0.000 | 0.652 *** | 0.009 |
SG + MM | 1.000 | 0.000 | 0.748 | 0.047 |
RF | Raw | 1.000 | 0.000 | 0.297 *** | 0.044 |
SG | 1.000 | 0.000 | 0.330 *** | 0.058 |
MM | 1.000 | 0.000 | 0.427 ** | 0.041 |
SG + MM | 1.000 | 0.000 | 0.476 | 0.033 |
Table 4.
Based on ASD spectrum, PLSDA combined with spectral preprocessing method was used to distinguish CK and EG processing on the same day. ACTR_Mean, ACTR_Std, ACVA_Mean, and ACVA_Std represent the mean training accuracy, the standard deviation of training accuracy, the mean validation accuracy, and the standard deviation of validation accuracy, respectively.
Table 4.
Based on ASD spectrum, PLSDA combined with spectral preprocessing method was used to distinguish CK and EG processing on the same day. ACTR_Mean, ACTR_Std, ACVA_Mean, and ACVA_Std represent the mean training accuracy, the standard deviation of training accuracy, the mean validation accuracy, and the standard deviation of validation accuracy, respectively.
Preprocessing Methods | Time | ACTR_Mean | ACTR_Std | ACVA_Mean | ACVA_Std |
---|
Raw | The 1st day | 1.000 | 0.000 | 0.808 | 0.042 |
The 2nd day | 1.000 | 0.000 | 0.843 | 0.091 |
The 3rd day | 1.000 | 0.000 | 0.829 | 0.057 |
The 5th day | 1.000 | 0.000 | 0.785 | 0.036 |
The 6th day | 1.000 | 0.000 | 0.756 | 0.076 |
SG + MM | The 1st day | 1.000 | 0.000 | 0.842 | 0.040 |
The 2nd day | 1.000 | 0.000 | 0.843 | 0.036 |
The 3rd day | 1.000 | 0.000 | 0.857 | 0.059 |
The 5th day | 1.000 | 0.000 | 0.770 | 0.036 |
The 6th day | 1.000 | 0.000 | 0.763 | 0.029 |
Table 5.
ASD spectra combined with spectral preprocessing were used to distinguish the accuracy of CK group and EG group at different times.
Table 5.
ASD spectra combined with spectral preprocessing were used to distinguish the accuracy of CK group and EG group at different times.
Preprocessing Methods | Treatment | ACTR_Mean | ACTR_Std | ACVA_Mean | ACVA_Std |
---|
Raw | CK | 1.000 | 0.000 | 0.624 | 0.014 |
EG | 1.000 | 0.000 | 0.630 | 0.020 |
SG + MM | CK | 1.000 | 0.000 | 0.664 | 0.041 |
EG | 1.000 | 0.000 | 0.773 | 0.054 |
Table 6.
The characteristic bands corresponding to the important metabolite categories and their attribution.
Table 6.
The characteristic bands corresponding to the important metabolite categories and their attribution.
Metabolite Category | Count | Functional Group 1 | Functional Group 2 | Functional Group 3 |
---|
Free fatty acids | 9 | ν C=O (1743 cm−1) | δ CH2/CH3 (1465 cm−1) | ν C-O, δ C-H (1160 cm−1) |
Phenolic acids | 6 | ν C=C (1625–1430 cm−1) | δ,ρ CH (1470–1435 cm−1) | ν C=O (1740–1705 cm−1) |
Flavonols | 5 | ν C-O (1310–1230 cm−1) | ν C-O-C (1160 cm−1) | ν C=O, C=C (1570–1540, 1535–1525, 1465–1445, 1420–1400 cm−1) |
Triterpene | 5 | ν C=O (1788–1633 cm−1) | δ C-H (1093, 1043, 900 cm−1) | ν O-H (3550–3250 cm−1) |
Organic acids | 4 | ν C-H (1200–900 cm−1) | ν C-O (1500–1200 cm−1) | ν O-H (3300–2500 cm−1) |
Table 7.
The calculation result of the overtone signal.
Table 7.
The calculation result of the overtone signal.
Source of Vibration | Fundamental Frequency | The First Overtone | The Second Overtone | The Third Overtone | The Merged Result |
---|
C-O (1570–1200 cm−1) | 1788–900 cm−1 | 2944–5848 nm | 2071–4115 nm | 1645–3268 nm | 840–2500 nm |
C=O (1788–1633 cm−1) |
C-H (1200–900 cm−1) |
C=C (1625–1430 cm−1) |
O-H | 3500–2500 cm−1 | 1504–2105 nm | 1058–1481 nm | 840–1176 nm |